Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Long-Term Investments (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Long-Term Investments for 14 consecutive years, with $308.5 million as the latest value for Q1 2026.

  • For Q1 2026, Long-Term Investments fell 41.94% year-over-year to $308.5 million; the TTM value through Mar 2026 reached $308.5 million, down 41.94%, while the annual FY2025 figure was $310.0 million, 51.43% down from the prior year.
  • Long-Term Investments hit $308.5 million in Q1 2026 for Agios Pharmaceuticals, down from $310.0 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $655.9 million in Q3 2024 and bottomed at $29.4 million in Q4 2023.
  • Average Long-Term Investments over 5 years is $309.4 million, with a median of $298.4 million recorded in 2022.
  • Year-over-year, Long-Term Investments tumbled 90.62% in 2023 and then skyrocketed 2068.58% in 2024.
  • Agios Pharmaceuticals' Long-Term Investments stood at $313.9 million in 2022, then crashed by 90.62% to $29.4 million in 2023, then surged by 2068.58% to $638.3 million in 2024, then plummeted by 51.43% to $310.0 million in 2025, then dropped by 0.5% to $308.5 million in 2026.
  • According to Business Quant data, Long-Term Investments over the past three periods came in at $308.5 million, $310.0 million, and $304.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.